The lab may feel like your second home. After all, you spend a large chunk of your life there. So it can be easy to fall into a routine and use whatever lab consumables are available. But what if those everyday items aren’t the best tools for the job? Using inappropriate products can mean unreliable results, leading to even more time at the lab bench, and potentially increasing costs. Let’s take a look at the top five lab essentials and highlight some key features you might wish to consider. Learn more about Corning's lab consumable offerings here: https://bit.ly/42vQyb4

The global pharmaceutical industry is constantly innovating, looking forward to discover the next class of therapies to treat and cure patients around the world. Cell and gene therapies, which fall into the broader category of drugs known as Advanced Therapy Medicinal Products (ATMPs) have emerged as an incredibly promising class of treatments that have shown the ability to treat and even cure many individuals with diseases for which there was little to no hope. Cell and gene therapies work by substituting the missing protein or cells causing the disease’s symptoms. Cell therapy treats diseases by restoring or altering certain sets of cells or by using cells to carry a therapy through the body. Gene therapy operates differently by replacing, inactivating or introducing genes into cells— either inside the body (in vivo) or outside of the body (ex vivo). Some therapies are considered both cell and gene therapies. These therapies work by modifying genes in specific types of cells and inserting them into the body. Current market forecasts predict the cell and gene therapy market to grow by almost $10B by 2026. A compound annual growth rate of more than 20%. American Pharmaceutical Review and Pharmaceutical Outsourcing magazine spoke with industry experts to learn how cell and gene therapies are changing the healthcare landscape and what needs to be done to bring these advanced therapies to patients.

Are “perverse incentives” responsible for the reproducibility crisis? Some experts believe that the pressure to secure research grants, promotions, and coveted post-doc positions, as well as publish in top-tier journals, is resulting in behavior that has fueled the reproducibility problem. Others believe the problem is more multifaceted and involves many groups including researchers, publishers, product manufacturers, professional societies and funding agencies. In this video, Biocompare examines the problem through interviews with all of stakeholder groups and presents some interesting potential solutions including more training for researchers, more data transparency from suppliers, more detailed guidelines from granting agencies and possibly more oversight from research institutions. Just as no one group is responsible for this problem, no one stakeholder group alone can solve this issue. Find out how you can be part of the solution by watching the video now. To see more of Biocompare's coverage of the reproducibility crisis, click here: http://www.biocompare.com/Reproducibility/ Follow Bicompare on LinkedIn: https://www.linkedin.com/company-beta/37127/ Check out Biocompare on Facebook: https://www.facebook.com/Biocompare Follow Biocompare on Twitter: https://twitter.com/biocompare